Steroid receptor/coactivator binding inhibitors: An update.

Area of Science:

• Molecular Endocrinology
• Drug Discovery
• Cancer Therapeutics

Background:

• Steroid receptors play crucial roles in various physiological processes.
• Dysregulation of steroid receptor signaling is implicated in diseases like cancer.
• Current therapies targeting steroid receptors often face challenges with resistance.

Purpose of the Study:

• To review recent advancements in small molecules and peptides designed to inhibit coactivator binding to steroid receptors.
• To focus on inhibitors targeting the coregulator binding groove (Activation Function-2) rather than the ligand-binding site.
• To highlight compounds evaluated in cell-based models for potential therapeutic applications.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of small-molecule and peptide inhibitors targeting steroid receptors.
• Focus on compounds assayed in cell-based models.

Main Results:

• Identification of novel small molecules and peptides that effectively block coactivator recruitment to steroid receptors.
• Demonstration that these inhibitors target the Activation Function-2 domain.
• Evidence suggesting potential efficacy against resistant forms of steroid receptor-driven diseases.

Conclusions:

• Coactivator binding inhibitors represent a promising therapeutic strategy for steroid receptor-related diseases.
• Targeting the Activation Function-2 site offers an alternative approach to overcome treatment resistance.
• Further development and clinical evaluation of these inhibitors are warranted.